Int Ophthalmol. 2025 Jun 12;45(1):240. doi: 10.1007/s10792-025-03590-7.
ABSTRACT
PURPOSE: To compare the intraocular pressure (IOP) lowering effect and safety of topical netarsudil 0.02% once daily with topical ripasudil 0.4% twice daily in primary open angle glaucoma (POAG) patients.
METHODS: A prospective, comparative, randomized study conducted on 140 eyes of patients diagnosed to have POAG, in a tertiary care hospital of Northern India. Patients divided into groups, A and B in a 1:1 ratio and were treated with ripasudil 0.4% or netarsudil 0.02% respectively and followed up. The mean diurnal IOP noted at 3rd week and 3rd month comparing it from baseline values, with their side effects.
RESULTS: At 3rd month, meandiurnal IOP for ripasudil 0.4% group ranged from 19.22 to 20.69 mmHg whereas for netarsudil group it was 17.11-18.47 mmHg, an intergroup statistically significant difference in IOP of 2.3 mmHg (p < 0.0001) noted. At 3rd month the difference from baseline was 2.77 mmHg (p = 0.048) for ripasudil and 4.64 mmHg (p = 0.001) for netarsudil. At the end of 3 months the adverse events were seen less in group B than group A (59.8% and 66.7% respectively. Eye irritation followed by conjunctival hyperemia was seen. Overall incidence of adverse events was 32.9% and 44.3% for topical netarsudil and ripasudil respectively.
CONCLUSION: Topical netarsudil 0.02% once daily was well tolerated with fewer side effects and in reducing IOP than topical ripasudil 0.4% twice daily dosing in POAG patients. Netarsudil 0.02% once daily may be considered an important option for the IOP control in POAG.
PMID:40504269 | DOI:10.1007/s10792-025-03590-7
